• Je něco špatně v tomto záznamu ?

The Role of Adjuvant Radiotherapy in the Treatment of Breast Cancer

I. Kolářová, B. Melichar, I. Sirák, J. Vaňásek, J. Petera, K. Horáčková, D. Pohanková, F. Ďatelinka, Z. Šinkorová, M. Vošmik

. 2024 ; 31 (3) : 1207-1220. [pub] 20240224

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007061

The role of postmastectomy radiotherapy and regional nodal irradiation after radical mastectomy is defined in high-risk patients with locally advanced tumors, positive margins, and unfavorable biology. The benefit of postmastectomy radiotherapy in intermediate-risk patients (T3N0 tumors) remains a matter of controversy. It has been demonstrated that radiotherapy after breast-conserving surgery lowers the locoregional recurrence rate compared with surgery alone and improves the overall survival rate. In patients with four or more positive lymph nodes or extracapsular extension, regional lymph node irradiation is indicated regardless of the surgery type (breast-conserving surgery or mastectomy). Despite the consensus that patients with more than three positive lymph nodes should be treated with radiotherapy, there is controversy regarding the recommendations for patients with one to three involved lymph nodes. In patients with N0 disease with negative findings on axillary surgery, there is a trend to administer regional lymph node irradiation in patients with a high risk of recurrence. In patients treated with neoadjuvant systemic therapy and mastectomy, adjuvant radiotherapy should be administered in cases of clinical stage III and/or ≥ypN1. In patients treated with neoadjuvant systemic therapy and breast-conserving surgery, postoperative radiotherapy is indicated irrespective of pathological response.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007061
003      
CZ-PrNML
005      
20240423155712.0
007      
ta
008      
240412s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/curroncol31030090 $2 doi
035    __
$a (PubMed)38534923
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kolářová, Iveta $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic $u Faculty of Health Studies, Pardubice University, 532 10 Pardubice, Czech Republic
245    14
$a The Role of Adjuvant Radiotherapy in the Treatment of Breast Cancer / $c I. Kolářová, B. Melichar, I. Sirák, J. Vaňásek, J. Petera, K. Horáčková, D. Pohanková, F. Ďatelinka, Z. Šinkorová, M. Vošmik
520    9_
$a The role of postmastectomy radiotherapy and regional nodal irradiation after radical mastectomy is defined in high-risk patients with locally advanced tumors, positive margins, and unfavorable biology. The benefit of postmastectomy radiotherapy in intermediate-risk patients (T3N0 tumors) remains a matter of controversy. It has been demonstrated that radiotherapy after breast-conserving surgery lowers the locoregional recurrence rate compared with surgery alone and improves the overall survival rate. In patients with four or more positive lymph nodes or extracapsular extension, regional lymph node irradiation is indicated regardless of the surgery type (breast-conserving surgery or mastectomy). Despite the consensus that patients with more than three positive lymph nodes should be treated with radiotherapy, there is controversy regarding the recommendations for patients with one to three involved lymph nodes. In patients with N0 disease with negative findings on axillary surgery, there is a trend to administer regional lymph node irradiation in patients with a high risk of recurrence. In patients treated with neoadjuvant systemic therapy and mastectomy, adjuvant radiotherapy should be administered in cases of clinical stage III and/or ≥ypN1. In patients treated with neoadjuvant systemic therapy and breast-conserving surgery, postoperative radiotherapy is indicated irrespective of pathological response.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a nádory prsu $x farmakoterapie $7 D001943
650    _2
$a mastektomie $7 D008408
650    _2
$a adjuvantní radioterapie $7 D018714
650    _2
$a lokální recidiva nádoru $x patologie $7 D009364
650    _2
$a segmentální mastektomie $7 D015412
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacky University, 779 00 Olomouc, Czech Republic
700    1_
$a Sirák, Igor $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic $1 https://orcid.org/0000000259723866 $7 xx0135409
700    1_
$a Vaňásek, Jaroslav $u Faculty of Health Studies, Pardubice University, 532 10 Pardubice, Czech Republic $u Oncology Centre, Multiscan, 532 03 Pardubice, Czech Republic
700    1_
$a Petera, Jiří $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic
700    1_
$a Horáčková, Kateřina $u Faculty of Health Studies, Pardubice University, 532 10 Pardubice, Czech Republic
700    1_
$a Pohanková, Denisa $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic
700    1_
$a Ďatelinka, Filip $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic
700    1_
$a Šinkorová, Zuzana $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence, 500 01 Hradec Králové, Czech Republic
700    1_
$a Vošmik, Milan $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic $1 https://orcid.org/0000000164977505 $7 xx0135408
773    0_
$w MED00165427 $t Current oncology $x 1718-7729 $g Roč. 31, č. 3 (2024), s. 1207-1220
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38534923 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155708 $b ABA008
999    __
$a ok $b bmc $g 2081204 $s 1216828
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 31 $c 3 $d 1207-1220 $e 20240224 $i 1718-7729 $m Current oncology $n Curr. oncol. $x MED00165427
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace